What is Fulgent Genetics's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Fulgent Genetics year over year?

What were the key takeaways from Fulgent Genetics’s earnings call?

What factors drove the changes in Fulgent Genetics's revenue and profit?

What were the key takeaways from Fulgent Genetics's earnings call?

What is Fulgent Genetics's gross profit margin?

Did Fulgent Genetics beat or miss consensus estimates last quarter?

What guidance did Fulgent Genetics's management provide for the next earnings period?

- **Revenue Resilience**: FY2025 revenue grew 14% to $322.7M, driven by AI and digital pathology investments. 2026 guidance of $350M (+8.5%) reflects offset from Bako/StrataDx acquisitions despite 70% loss of largest customer volume. 
- **AI-Driven Efficiency**: 100% digital pathology adoption and 12 new AI modules to enhance pathologist productivity and reduce costs. 
- **Therapeutic Momentum**: FID-007 Phase II interim data expected at ASCO 2026, with Phase III启动计划在2027年上半年. 
- **Financial Strength**: $705.5M cash on hand, with $685M expected in 2026 (excluding tax refund delay).

**【CEO Summary Section】**
- **Strategic Progress**: CEO Ming Hsieh highlighted progress in AI, digital pathology, and therapeutic development. The company transitioned to a proprietary AI imaging system (Eziopath) and launched RNA-integrated whole genome sequencing. 
- **Therapeutic Pipeline**: FID-007 Phase II trial enrollment completed, with interim data expected at ASCO 2026. FID-002 Phase I dose escalation ongoing. 
- **2026 Outlook**: Anticipates revenue impact from largest customer moving 70% of testing in-house, but expects offset from Bako/StrataDx acquisitions and AI-driven efficiency gains.

**【CFO Financial Commentary】**
- **FY2025 Results**: Revenue $322.7M (+14% YoY), Non-GAAP EPS $0.42 (beat guidance). Gross margin 41% (non-GAAP). 
- **2026 Guidance**: Revenue $350M (+8.5%), Non-GAAP EPS loss $1.45. Key drivers: $50M+ from Bako/StrataDx, 31% growth in Precision Diagnostics (excluding largest customer). 
- **Cash Position**: $705.5M at year-end, expecting $685M in 2026 (excluding $106M tax refund delay). 

**【Q&A Highlights】**
- **Customer Impact**: Largest customer revenue to drop from $70.8M in 2025 to $11.8M in 2026. Management confident in offsetting with Bako/StrataDx and organic growth. 
- **M&A Strategy**: Focus on AI, digital pathology, and synergistic acquisitions. Bako/StrataDx adds 20-30 sales reps for cross-selling opportunities. 
- **AI Efficiency**: 100% digital pathology adoption, with 12 new AI modules planned for 2026 to improve pathologist productivity. 
- **Therapeutic Spend**: $26M allocated for clinical trials, with FID-007 Phase III启动计划在2027年上半年。

Fulgent Genetics, Inc.(FLGT)-20260227-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 lab services revenue up 15% YoY to $84.1M, driven by new product launches (ultrarapid WGS, Beacon K). 
- **Therapeutic Pipeline**: FID-007 Phase II shows 44-59% ORR, PFS 7.8M vs. 2.3M control.
- **Financial Health**: Non-GAAP EPS $0.14, gross margin 44.3%, 2025 guidance raised to $325M (+15% YoY). 
- **AI & Digital Pathology**: EZPath IMS deployment enables 48-hour WGS reports, reducing costs by $67.9M in Q3.
- **Shareholder Value**: $139.6M remaining under buyback program; 2025 cash position $787.7M.


**【CEO Summary Section】**
- Q3 2025 revenue reached $84.1 million, up 3.1% sequentially and 15% year-over-year, driven by lab services growth and therapeutic pipeline progress.
- FID-007 Phase II trial shows ORR of 44% and 59% across dose levels, with PFS of 7.8 months vs. 2.3 months for standard care.
- FID-022 Phase I trial completes first dose level, with second dose level initiated.

**【CFO Financial Commentary】**
- Non-GAAP EPS: $0.14 (up from $0.10 in Q2), reflecting $4.5 million net income.
- Gross margin: 44.3% (non-GAAP), up 150 basis points YoY, driven by operational efficiency.
- 2025 guidance raised to $325 million (15% YoY growth), with non-GAAP operating margin improving to -10%.

**【Q&A Highlights】**
- Collections timing resolved, with Q3 collections improving sequentially.
- New products: ultrarapid whole genome sequencing (NICU-focused) and Beacon K (1,000-gene panel) launched.
- Therapeutic development: Phase III for FID-007 expected to begin in 2026 with ~$60 million cost.
- Digital pathology IMS (EZPath) deployment enhances AI-driven workflows.
- 2025 cash position: $787.7 million (up $67.9M YoY), with $139.6M remaining under share buyback program.


Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Core lab services up 14% y/y to $81.8M
- **Margin Expansion**: 44.2% non-GAAP gross margin
- **Pipeline Momentum**: $30M Phase II FID-007 trial enrolling 32 pts
- **Clinical Readouts**: 2026 data for FID-007, 2027 for FID-022
- **Share Buybacks**: $110M repurchased since 2022
- **R&D Investment**: $25M annual spend supporting 14% y/y revenue growth
- **Exome Sequencing**: 10-15% diagnostic yield improvement with RNA
- **AP Expansion**: 11% QoQ growth via new salesforce
- **VA Contract**: $7M y/y increase in Precision Diagnostics
- **Managed Care**: 20+ new contracts YTD
- **Balance Sheet**: $777M cash for M&A/clinical trials
- **EPS Guidance**: -$2.10 (GAAP), -$0.35 (non-GAAP)
- **Key Risks**: Regulatory delays, enrollment challenges, economic sensitivity

**【CEO Opening Remarks】**
- Q2 2025 revenue of $81.8 million (+11% QoQ, +14% YoY), driven by 16% y/y growth in core lab services.
- Clinical pipeline progress: FID-007 Phase II trial enrolling 32 pts (targeting recurrent/metastatic HNSCC), FID-022 Phase I trial launched for solid tumors.
- 2025 guidance updated: Core revenue raised to $320M (from $310M), reflecting 14% y/y growth.
- Gross margin improved to 44.2% (non-GAAP) due to operational efficiency.

**【CFO Financial Highlights】**
- Non-GAAP EPS of $0.07 (vs. $0.65 prior), driven by $2.1M net income.
- Operating expenses +17% QoQ to $43.9M, reflecting R&D and sales investments.
- Cash position remains strong at $777.5M, supporting M&A (e.g., $4M ANP Tech acquisition).
- 2025 GAAP EPS guidance updated to -$2.10 (from -$1.95), reflecting onetime charges.

**【Q&A Key Themes】**
- **AP Growth**: 11% QoQ expansion via new salesforce, winning 35M+ new covered lives.
- **Precision Diagnostics**: $7M y/y increase from VA contract & Foundation Medicine partnership.
- **Exome Sequencing**: 10-15% diagnostic yield improvement with RNA integration.
- **R&D Pipeline**: $30M Phase II FID-007, $8M Phase I FID-022, with potential 2026 data readouts.
- **Managed Care**: 20+ new contracts YTD, expanding in-network coverage.

**【Strategic Priorities】**
1. Expand lab services market share through salesforce expansion
2. Accelerate clinical trials with $25M annual R&D spend
3. Maintain 40%+ gross margin via operational efficiency
4. Prudent capital allocation (repurchased $110M shares)
5. Leverage AI/automation for competitive differentiation

**【Risk Factors】**
- Clinical trial enrollment delays
- Regulatory approvals for new tests
- Managed care contract renewals
- R&D cost overruns
- Economic conditions impacting healthcare spending

Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript

- **Core Growth**: Q1 lab services revenue up 10% YoY, driven by 17.8% precision diagnostics expansion and 9.5% anatomic pathology gain.
- **Therapeutic Momentum**: $25M R&D spend for 2025, with FID-007 Phase 2 enrollment on track and FID-022 Phase 1 starting soon.
- **Digital Pathology Lead**: 85%+ slides digitized, enabling AI-assisted workflows and remote pathologist recruitment.
- **Financial Strength**: $814M cash, $10.9M spent on buybacks YTD, and 2025 core revenue guide of $310M (+10% YoY).
- **Regulatory Relief**: FDA LDT rule overturned, reducing compliance burden for lab tests.

**【CEO Summary Section】**
- Q1 2025 revenue growth driven by core lab services, with therapeutic pipeline progressing: Phase 2 trial for FID-007 (17 patients treated, 23 enrolled) and Phase 1 for FID-022 (nanoencapsulated FM38 for solid tumors) on track.
- Therapeutic R&D costs expected at $25M for 2025, with FID-007 targeting EGFR+ and non-EGFR head & neck cancer patients.
- Strong financial position with $814.6M cash as of Q1, supporting strategic initiatives.

**【CCO Lab Services Update】**
- **Precision Diagnostics**: +17.8% YoY ($6.7M), led by reproductive health, legacy tests, and Beacon Expanded Carrier Screening. Digital pathology adoption >85%, with $1M+ in Q1 digital billing.
- **Anatomic Pathology**: +9.5% YoY ($2.2M), benefiting from improved sales execution and remote pathologist recruitment (60+ sub-specialists).
- **Biopharma Services**: +51.3% YoY ($1.4M), though Q1 down 33.7% sequentially due to contract timing. Expanded capabilities (e.g., RNA-Integrated Sequencing) driving pipeline growth.

**【CFO Financial Highlights】**
- Q1 2025 revenue: $73.5M (ex-COVID), with non-GAAP gross margin 41% (vs. 38.6% GAAP).
- Non-GAAP operating loss: $13.8M (19% of revenue), driven by $37.4M operating expenses.
- 2025 guidance: Core revenue $310M (+10% YoY), non-GAAP gross margin >40%, operating margin -15%, and cash ending at $770M.
- $10.9M spent on share buybacks YTD, with $139.6M remaining under $250M program.

**【Q&A Key Takeaways】**
- **Guidance Rationale**: Management cautious on raising Q1 beat due to lumpy biopharma and need for more visibility on VA/Foundation Medicine ramp.
- **Therapeutic Pipeline**: FID-007 Phase 2 cost $10M+ over multi-years; FID-022 Phase 1/1b cost $8M. Targeting heavily pre-treated patients with limited options.
- **Sales & Marketing**: Q2+ spend to rise to $10-11M/Q, supporting new hires in rare disease, reproductive health, and pathology.
- **LDT Regulation**: Court ruling halts FDA oversight, reducing regulatory uncertainty for lab-developed tests.
- **M&A Appetite**: Actively evaluating tuck-in opportunities to expand distribution and tech capabilities.

Fulgent Genetics (FLGT)-2 May 25-2025 Q1 Earnings call transcript

- **2024 Performance Highlight**: Core revenue of $281.2 million (+7% YoY) exceeded guidance, driven by AP (9% QoQ growth) and Precision Diagnostics (23% YoY).
- **Therapeutic Pipeline Momentum**: FID-007 Phase II trial on track to enroll 46 patients by late 2025; FID-022 Phase Ib trial to begin in Q2 2025 with $8 million budget.
- **2025 Outlook**: 10% core revenue growth to $310 million, non-GAAP gross margin >40%, and $25 million therapeutic R&D spend.
- **Financial Strength**: $828.6 million cash balance; $147 million remaining under stock buyback program.

**【CEO Summary Section】**
- Core revenue for 2024 reached $281.2 million, exceeding guidance of $280 million, with 7% year-over-year growth.
- Therapeutic development progress: Phase II trial of FID-007 in head and neck cancer has dosed 17 patients, with plans to complete enrollment of 46 patients by late 2025. Phase Ib trial for FID-022 (nanoencapsulated SN-38) is expected to begin in Q2 2025.
- Laboratory services growth: Anatomic Pathology (AP) saw 9% sequential growth in Q4, driven by improved turnaround times and market share gains. Precision Diagnostics grew 23% YoY, fueled by new product launches like RISE (RNA integrated sequencing) and KNOVA NIPT.
- Biopharma services surged 56% QoQ in Q4, reflecting expanded capabilities in proteomics and spatial biology.

**【CFO Financial Commentary】**
- GAAP loss for 2024 was $42.7 million, while non-GAAP income was $15 million. Q4 non-GAAP gross margin improved to 44.2%, up from 41.8% in Q3.
- 2025 financial outlook: Core revenue expected to grow 10% to $310 million, with non-GAAP gross margin >40%. Therapeutic development cash burn projected at $25 million.
- Cash position remains strong at $828.6 million as of Q4, with $147 million remaining under the stock repurchase program.

**【Q&A Key Takeaways】**
- FID-007 Phase II trial: $10 million budget on track; preliminary data to be presented at ASCO 2025. Head and neck cancer is the primary focus, but expansion into other solid tumors is planned.
- Q4 growth drivers: AP sales team expansion, new client wins in Precision Diagnostics, and biopharma services pipeline expansion.
- 2025 challenges: Seasonal fluctuations in AP (Q1), variable biopharma revenue, and $1.95 GAAP EPS loss due to R&D investments.

Actual																											-0.01	0.15	0.31	0.04	0.04	0.07	0.14	0.16
Forecast																											-0.3189	-0.2987	-0.1538	-0.1227	-0.1794	-0.1848	-0.2242	0.0298
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+96.86%	+150.22%	+301.56%	+132.60%	+122.30%	+137.88%	+162.44%	+436.91%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	64.48M	71.03M	71.74M	76.21M	73.46M	81.80M	84.07M	83.34M
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	65.36M	69.07M	71.72M	74.86M	71.26M	76.21M	81.43M	85.38M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.34%	+2.84%	+0.04%	+1.81%	+3.09%	+7.34%	+3.24%	-2.39%

FLGT

FLGT fundamentals

FLGT Q4 2025 Earnings

Earnings Call

You can ask Aime

FLGT

FLGT fundamentals

FLGT Q4 2025 Earnings

Earnings Call

FLGT Earnings Call Summary for Q4/20258:30 AM on Feb 27, 2026

FLGT Earnings Call Summary for Q3/20258:30 AM on Nov 7, 2025

FLGT Earnings Call Summary for Q2/20258:30 AM on Aug 1, 2025

FLGT Earnings Call Summary for Q1/20258:30 AM on May 2, 2025

FLGT Earnings Call Summary for Q4/20248:30 AM on Feb 28, 2025

You can ask Aime